AHR and neoplasm: Here, we found that ITE, an AHR agonist that suppressed immunity in EAE and experimental colitis [19,20], activated anti-tumor immunity when combined with PD1 antibodies, suggesting that the efforts for targeting AHR shall go beyond searching for antagonists.